Compassionate use of dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion in a clinical setting

Acta Ophthalmologica

Volumn 90, Issue 4, 2012, Pages

  Parodi, Maurizio Battaglia ^a   Iacono, Pierluigi ^b   Cascavilla, Marialucia ^a   Zucchiatti, Ilaria ^a   Bandello, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; DEXAMETHASONE;

ADULT; BEST CORRECTED VISUAL ACUITY; CATARACT; CENTRAL FOVEA THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; COMPASSIONATE USE; DRUG EFFICACY; DRUG IMPLANT; EYE EXAMINATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; LETTER; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA EDEMA; VISUAL SYSTEM PARAMETERS;

COMPASSIONATE USE TRIALS; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 84861626043     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02238.x     Document Type: Letter

References (4)

1. Brown DM, Campochiaro PA, Singh RP, et al., (2010): Ranibizumabfor macular edema following central retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology 117: 1124-1133.
2. Ferrara DC, Koizumi H, &, Spaide RF, (2007): Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 144: 864-871.
3. Haller JA, Bandello F, Belfort R Jr, et al., (2010): Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117: 1134-1146.
4. Ip MS, Scott IU, VanVeldhuisen PC, et al., (2009): A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vrs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127: 1101-1114.